Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Griffin Securities, Inc.
$69.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Soligenix Inc Receives IND Clearance From FDA To Initiate Clinical Program To Evaluate SGX942 For Treatment Of Oral Mucositis


Wednesday, 27 Mar 2013 07:00am EDT 

Soligenix Inc announced that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients. Clearance of the IND allows Soligenix to initiate a Phase 2, randomized, double-blind, placebo-controlled, dose-escalating clinical study of SGX942 in patients being treated for head and neck cancer. The trial is expected to be initiated in the second half of 2013. 

Company Quote

1.0
-0.01 -0.99%
3:56pm EST